These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 24522402)

  • 1. Population pharmacokinetics of afatinib, an irreversible ErbB family blocker, in patients with various solid tumors.
    Freiwald M; Schmid U; Fleury A; Wind S; Stopfer P; Staab A
    Cancer Chemother Pharmacol; 2014 Apr; 73(4):759-70. PubMed ID: 24522402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I study of daily afatinib, an irreversible ErbB family blocker, in combination with weekly paclitaxel in patients with advanced solid tumours.
    Suder A; Ang JE; Kyle F; Harris D; Rudman S; Kristeleit R; Solca F; Uttenreuther-Fischer M; Pemberton K; Pelling K; Schnell D; de Bono J; Spicer J
    Eur J Cancer; 2015 Nov; 51(16):2275-84. PubMed ID: 26296295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of afatinib, a selective irreversible ErbB family blocker, in patients with advanced solid tumours.
    Wind S; Schmid M; Erhardt J; Goeldner RG; Stopfer P
    Clin Pharmacokinet; 2013 Dec; 52(12):1101-9. PubMed ID: 23813493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Pharmacokinetics and Pharmacodynamics of Afatinib.
    Wind S; Schnell D; Ebner T; Freiwald M; Stopfer P
    Clin Pharmacokinet; 2017 Mar; 56(3):235-250. PubMed ID: 27470518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II, open-label trial to assess QTcF effects, pharmacokinetics and antitumor activity of afatinib in patients with relapsed or refractory solid tumors.
    Molife LR; Rudman SM; Alam S; Tan DS; Kristeleit H; Middleton G; Propper D; Bent L; Stopfer P; Uttenreuther-Fischer M; Wallenstein G; de Bono J; Spicer J
    Cancer Chemother Pharmacol; 2013 Dec; 72(6):1213-22. PubMed ID: 24085260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetics of nintedanib, an inhibitor of tyrosine kinases, in patients with non-small cell lung cancer or idiopathic pulmonary fibrosis.
    Schmid U; Liesenfeld KH; Fleury A; Dallinger C; Freiwald M
    Cancer Chemother Pharmacol; 2018 Jan; 81(1):89-101. PubMed ID: 29119292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors.
    Guo F; Letrent SP; Sharma A
    Cancer Chemother Pharmacol; 2007 Nov; 60(6):799-809. PubMed ID: 17285315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase 2 trial of afatinib, an ErbB family blocker, in solid tumors genetically screened for target activation.
    Kwak EL; Shapiro GI; Cohen SM; Becerra CR; Lenz HJ; Cheng WF; Su WC; Robohn M; Le Maulf F; Lobmeyer MT; Chand VK; Iafrate AJ
    Cancer; 2013 Aug; 119(16):3043-51. PubMed ID: 23775486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetics and dosing implications for cobimetinib in patients with solid tumors.
    Han K; Jin JY; Marchand M; Eppler S; Choong N; Hack SP; Tikoo N; Bruno R; Dresser M; Musib L; Budha NR
    Cancer Chemother Pharmacol; 2015 Nov; 76(5):917-24. PubMed ID: 26365290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetics of nintedanib in patients with idiopathic pulmonary fibrosis.
    Schmid U; Doege C; Dallinger C; Freiwald M
    Pulm Pharmacol Ther; 2018 Feb; 48():136-143. PubMed ID: 29133080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Afatinib pharmacokinetics and metabolism after oral administration to healthy male volunteers.
    Stopfer P; Marzin K; Narjes H; Gansser D; Shahidi M; Uttereuther-Fischer M; Ebner T
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):1051-61. PubMed ID: 22200729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetics of HM781-36 (poziotinib), pan-human EGF receptor (HER) inhibitor, and its two metabolites in patients with advanced solid malignancies.
    Noh YH; Lim HS; Jung JA; Song TH; Bae KS
    Cancer Chemother Pharmacol; 2015 Jan; 75(1):97-109. PubMed ID: 25377158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase I dose-escalation study of afatinib combined with nintedanib in patients with advanced solid tumors.
    Gordon MS; Springett GM; Su YB; Ould-Kaci M; Wind S; Zhao Y; LoRusso PM
    Future Oncol; 2015; 11(10):1479-91. PubMed ID: 25963426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors.
    Yap TA; Vidal L; Adam J; Stephens P; Spicer J; Shaw H; Ang J; Temple G; Bell S; Shahidi M; Uttenreuther-Fischer M; Stopfer P; Futreal A; Calvert H; de Bono JS; Plummer R
    J Clin Oncol; 2010 Sep; 28(25):3965-72. PubMed ID: 20679611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population Pharmacokinetics of Capivasertib in Patients with Advanced or Metastatic Solid Tumours.
    Fernandez-Teruel C; Cullberg M; Eberlein C; Barry ST; Zhou D
    Clin Pharmacokinet; 2024 Aug; 63(8):1191-1204. PubMed ID: 39127854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I study of volasertib combined with afatinib, in advanced solid tumors.
    Machiels JP; Peeters M; Herremans C; Surmont V; Specenier P; De Smet M; Pilz K; Strelkowa N; Liu D; Rottey S
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):843-51. PubMed ID: 26349473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of single-agent axitinib across multiple solid tumor types.
    Tortorici MA; Cohen EE; Pithavala YK; Garrett M; Ruiz-Garcia A; Kim S; Fruehauf JP
    Cancer Chemother Pharmacol; 2014 Dec; 74(6):1279-89. PubMed ID: 25336084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetics of raltitrexed in patients with advanced solid tumours.
    Blair EY; Rivory LP; Clarke SJ; McLachlan AJ
    Br J Clin Pharmacol; 2004 Apr; 57(4):416-26. PubMed ID: 15025739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors.
    Li J; Karlsson MO; Brahmer J; Spitz A; Zhao M; Hidalgo M; Baker SD
    J Natl Cancer Inst; 2006 Dec; 98(23):1714-23. PubMed ID: 17148773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I dose-escalation study of afatinib, an ErbB family blocker, plus docetaxel in patients with advanced cancer.
    Marshall J; Shapiro GI; Uttenreuther-Fischer M; Ould-Kaci M; Stopfer P; Gordon MS
    Future Oncol; 2013 Feb; 9(2):271-81. PubMed ID: 23414476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.